Delivery of therapeutic genes to a large region of the retina with minimal damage from intraocular surgery is a central goal of treatment for retinal degenerations. Recent studies have shown that AAV9 can reach the central nervous system (CNS) and retina when administered systemically to neonates, which is a promising strategy for some retinal diseases. We investigated whether the retinal transduction efficiency of systemically delivered AAV9 could be improved by mutating capsid surface tyrosines, previously shown to increase the infectivity of several AAV vectors. Specifically, we evaluated retinal transduction following neonatal intravascular administration of AAV9 vectors containing tyrosine to phenylalanine mutations at two highly conserved sites. Our results show that a novel, double tyrosine mutant of AAV9 significantly enhanced gene delivery to the CNS and retina, and that gene expression can be restricted to rod photoreceptor cells by incorporating a rhodopsin promoter. This approach provides a new methodology for the development of retinal gene therapies or creation of animal models of neurodegenerative disease.
INTRODUCTION
Numerous retinal degenerative diseases are caused by single gene mutations that lead to either loss of protein function or gain of deleterious properties. Recently, adeno-associated viral vectormediated gene therapy has been successful in three separate clinical trials for treating the monogenic retinal dystrophy LCA2 caused by mutations in the retinoid isomerase retinal pigment epithelium (RPE)65. [1] [2] [3] These clinical trials clearly demonstrate that AAVmediated gene replacement therapies are an effective strategy for treating inherited retinal degeneration. In addition, they demonstrate proof of concept for ocular gene therapy, which hopefully can be extended to treat dominant disease involving gain of function mutations via the delivery of gene constructs that induce RNA interference.
Reviewing the positive LCA2 results underscores the importance of the surgical route of delivery to successful treatment outcome. The vast majority of retinal disease mutations affect photoreceptors and the RPE. 4 Vector administration into the subretinal space, in close proximity with these cells, has been preferable for gene replacement strategies targeting the outer retina. This approach is highly effective at generating localized expression of the transgene at levels sufficient to correct the retinal degeneration phenotype in LCA2 5 or where a diffusible factor is secreted from a group of infected cells in sufficient quantities to benefit the whole tissue. 6 However, subretinal injections are highly invasive and induce a transient retinal detachment, which is damaging to the photoreceptors.
An ideal approach to address retinal dystrophies that affect large areas of the retina would be to deliver the viral vector into the vitreous cavity. Unfortunately, there are a number of formidable barriers impeding gene delivery to the retina from the vitreous such as diffusion in the vitreous cavity and sequestering of viral particles in the inner limiting membrane. Although much progress has been made in the understanding of barriers to retinal transduction from the vitreous for AAV 7, 8 as well as improving the limited transduction of the naturally occurring serotypes by rational 9,10 and directed evolution approaches 11, 12 major obstacles remain in reaching therapeutically effective levels of gene expression, especially in larger animals where the inner limiting membrane is significantly thicker than in rodents. 13 An alternative approach for transducing large areas of retina is to administer vectors through the ocular vasculature. The retina is a highly vascularized structure with the highest oxygen consumption per weight of any human tissue. 14 The retina is nourished by a dual blood supply from the choroidal capillaries (supplying the outer retina) and by branches of the central retinal artery (supplying two thirds of the inner neural retina) (Figure 1 ). Vectors that can penetrate the blood-retinal barrier have the potential to access both inner and outer retinal layers. Although administration of gene delivery vehicles from the vasculature entails greater immunological risks, 15 it may be particularly promising in neonates where the immaturity of the newborn immune system leads to a 'physiological immunodeficiency' that encompasses all arms of the host response.
It was recently demonstrated that the retina can be transduced via neo-natal systemic administration of AAV, 16 though the utility of this seminal study has been somewhat limited to date by the relatively low levels of gene expression observed in limited retinal cell types, potentially because of the relatively low dosages used. Importantly, recent reports have shown that the central nervous system can be very effectively transduced via systemic administration [17] [18] [19] and the higher doses and use of self-complimentary vector genomes in these studies 20 may have contributed to this capability. These results suggest that improving the vector delivery system holds promise for enhancing retinal transduction while limiting the number of viral particles necessary to achieve sufficient levels of protein expression.
The AAV capsid is a critical determinant of vector transduction efficiency, mediating vector binding to cell surface receptors, internalization, cytoplasmic trafficking to the nuclear membrane and vector genome release. 21 It has been shown that tyrosines exposed on the AAV capsid surface can undergo tyrosine kinase-mediated phosphorylation, leading to ubiquitination and degradation of viral particles. Site-directed tyrosine to phenylalanine (Y-F) mutagenesis of one or more of the seven capsid surface-exposed AAV tyrosine residues in the VP3 common region has been reported to protect vector particles from proteasome degradation and yield significant increases in the transduction efficiency of mutant vectors relative to their wild-type counterparts. 9, 22 For example, AAV2, AAV8 or AAV9 vectors containing single Y-F point mutations on two of the seven surface-exposed capsid tyrosine residues are significantly more efficient at transduction of retinal cells when injected subretinally or intravitreally. 9 Here, we investigate whether retinal transduction via intravenous delivery to neonatal mice is enhanced by using AAV9 vector variants containing single or double Y-F mutations. We report that our double tyrosine mutant exhibits robust transgene expression in all retinal layers following a single intravascular injection in neonates. The potential to transduce photoreceptors and RPE cells (the targets of most inherited retinal degenerations)-as well as ganglion cells, amacrine cells and Müller glia-following systemic vector delivery represents a promising alternative to surgically traumatic subretinal injections that are currently necessary to transduce these cell types and opens new avenues in experimental gene therapy. Furthermore, the ability to efficiently target the photoreceptor and RPE cells of the retina bilaterally suggests this technology can be used to generate primate animal models of retinal degeneration. 23 For example, a novel transgenesis approach based not on germ line transgenesis, but instead harnessing AAV vectors to overexpress causative, mutant RP genes in the photoreceptors of models such as the macaque, could offer an attractive strategy to generate primate models of retinal degeneration. 24 
RESULTS AND DISCUSSION
Quantitative and histological comparison of AAV9, AAV9-1YF vs AAV9-2YF-mediated green fluorescent protein (GFP) expression Single phenylalanine (F) to tyrosine (Y) substitutions at positions 446 or 731 have been shown to increase retinal transduction by AAV9 following intraocular administration. 9 On the basis of these findings, we introduced a single tyrosine mutation at position 446 of AAV9 either alone (AAV9-1YF) or in combination with additional mutation at position 731 (AAV9-2YF).
Histology, fundus imaging and reverse transcriptase (RT)-PCR were used to quantify levels of GFP expression resulting from AAV9 and its tyrosine-mutated variants. Retinal flatmounts from pups 1 week post injection exhibited strong GFP expression in the retinal ganglion cells (RGC) (Supplementary Figure 1) , indicating a very early onset of gene expression. Two weeks after injection, at eyelid opening in pups, fundus imaging was performed, and the highest levels of GFP fluorescence were detected with AAV9-2YF (Figures 1b-d ). AAV9-1YF showed lower levels of GFP expression compared with AAV9-2YF but higher than AAV9 (Figure 1c) . We evaluated the amounts of GFP expression in a more quantitative fashion, by performing RT-PCR on pooled RNA extracted from retinal lysates obtained from pups injected with each of the viruses (n¼5 for AAV9, n¼4 AAV9-1YF Following these observed enhancements in GFP expression using the mutant AAV9 capsids, we evaluated the histological expression patterns of GFP in the retinal layers via confocal microscopy 8 weeks after injection. In agreement with the fundus images, the retinas that received AAV9-2YF exhibited an average of 3.3-fold more GFP in all retinal layers excluding the RPE (Supplementary Figures 1b and c) . Confocal z-stacks spanning the entire length of the retina showed GFP expression in all retinal layers for AAV9-2YF, as depicted in a 3D reconstruction side view (Figure 1f) .
GFP expression obtained with AAV9 was compared with its tyrosine-mutated counterparts; to do so the microscope was adjusted to the fluorescence intensity using the AAV9-2YF retina, and the same settings were retained for all subsequent acquisitions at each of the retinal layers. For each image, a Â10 objective was used to image 212Â212 mm fields next to the optic nerve head. Confocal z-stacks spanning 5-15 mm of the RGC layer, inner nuclear layer, photoreceptor layer, and RPE cells were acquired and merged (Figures 2a-l) . Our results consistently show that GFP expression is stronger with AAV9-2YF in each layer (see Supplementary Figures 2b and c for quantification of the GFP intensity in each layer). The most striking differences between the wild-type AAV9 and AAV9-2YF are observed in the number of transduced inner retinal cells and photoreceptor cells (Figures 2a-i) . In 212Â212 mm regions of the retinas close to the optic nerve head represented in Figure 2 , we found 112 GFP (+) cells in the RGC layer with AAV9 compared with 344 using AAV9-2YF. In the inner nuclear layer there were 222 GFP (+) cells for AAV9 and 606 for AAV9-2YF. A total of 218 GFP (+) photoreceptors were found using AAV9 compared with 823 with AAV9-2YF.
All vectors lead to significant levels of expression in the RPE and RGC cells (Figures 2 and 3) . Interestingly, however, an insignificant number of bipolar cells were transduced with AAV9-2YF or other capsid variants (Figures 3g-i) . Higher magnification images of the AAV-2YF-treated retinas further reveal transgene expression in the RGC layer (Figure 3j , with NeuN staining in red), the inner nuclear layer (Figure 3k ) and the outer nuclear layer (Figure 3l) . Additional, histological examination of the transduced retinas reveals striking differences, notably in the transduction of inner nuclear layer and photoreceptor cells (Figures 3a-i) . These observations correlate with the anatomical and physiological features of the retinal blood supply (Figure 1a) . That is, fenestrated choroidal vessels perfuse the outer retina and provide vector access to the basolateral RPE, whereas, arteries and veins lying within the nerve fiber layer give rise to fine capillaries that perfuse the inner retina. Thus, a gradient of GFP expression could result from AAV transport into the retina from the inner and outer blood supplies, with the RPE and ganglion cells closest to the initial sources of vector. As predicted by the anatomy, we observe the strongest transduction in the inner and outermost layers of the retina with the wild-type AAV9 virus. Introduction of tyrosine mutations enables more efficient transduction of the middle retina, which previously had undetectable levels of expression with the wild-type AAV9.
Expression in the mouse brain using AAV9 and its tyrosine-mutated counterparts The enhanced retinal transduction by AAV9-2YF compared with wild-type AAV9 led us to examine transduction of various brain regions. Analogous increases in transduction levels were observed with AAV9-2YF (left column) compared with AAV9 (right column) in all brain regions examined (Figures 4a-h, Supplementary Figure 3) . Consistent with previous reports for AAV9, GFP-positive cells included both neurons and astrocytes throughout the brain, 17 with variations in glial or neuronal tropism of the vectors varying depending upon the brain region examined (Supplementary Figure 3) . In the hippocampus, AAV9-2YF gave rise to high levels of expression in pyramidal neurons in the CA 1, 2 and 3, in the fimbria (Figures 4i  and j) as well as numerous granule cells in the dentate gyrus, alongside astrocytes. We made similar observations for AAV9, with the exception of observing fewer GFP-expressing astrocytes and fewer granular cells in this region. In the striatum, with AAV9-2YF we observe expression in what appears to be medium spiny neurons as well as interneurons and astrocytes, whereas with AAV9 we observe sparse and faint GFP expression in neurons with only a few transduced astrocytes. In the cortex, AAV9-2YF leads to expression in pyramidal neurons in all shows a z-projection image collected from the RPE flatmounts corresponding to the retinas. All stacks were acquired using identical acquisition parameters. The acquisition parameters were initially tuned for retinas transduced with AAV9-2YF, then used for all retinas.
Systemic retinal transduction with AAV9 variants D Dalkara et al cortical layers as well as some astrocytes. Similar expression patterns were observed with AAV9, although the extent and level of expression were lower in this region. Finally, in the cerebellum AAV9-2YF generated to pronounced labeling of Purkinje cells, granule cells and astrocytes, whereas AAV9 mediated lower expression in neurons. High level of GFP expression was also seen in the hypothalamus (data not shown). This advance has implications for AAV9-mediated central nervous system gene delivery, particularly for diseases such as spinal muscular atrophy. 18 The use of the double tyrosine mutant AAV9 in future work may enable a reduction in the number of viral particles required to achieve similar rescue effects. This may be advantageous in lowering the risks of immune response to the virus. In addition to these applications, this technology offers an alternative to traditional transgenesis for basic neuroscience research.
Strong photoreceptor-specific expression using AAV9-2YF with a rhodopsin promoter In both clinical and experimental gene therapy applications using systemic delivery, it will likely be necessary to restrict transgene expression to a specific cell type. To this end, we replaced the ubiquitous CAG promoter used in the initial experiments with a mouse rhodopsin promoter and examined the expression patterns 3 weeks post injection. Our data show expression restricted to photoreceptor cells with no detectable expression in all other retinal cells ( Figure 5 ) or in the brain (data not shown). This technology may thus be used to rapidly and economically generate somatic central nervous system transgenic animal models or gene knockdown animal models of photoreceptor diseases without costly and time intensive genetic manipulations. Most importantly, this approach offers the possibility of generating large animal models of diseases in which mutant proteins (that is, a-synuclein, P23H rhodopsin) that induce neurodegeneration can be expressed in the afflicted regions of the brain 24 or retina with AAV9-2YF-mediated transgenesis.
The clinical relevance of systemic gene delivery for treating retinal degenerations will more critically depend upon the ability to restrict gene expression to the cell type(s) of interest, and this specificity may be achieved through the use of cell specific promoters-as demonstrated here-or via miRNA strategies. 25 One major obstacle to the application of this technology in a clinical context is likely the risks of immune response to the capsid, which may pose significant safety concerns relative to local injections within the highly compartmentalized and immune privileged eye. 15 Regardless, the systemic injection of AAV is likely to be useful in the development of experimental gene therapies for inherited retinal degeneration, as many animal models of retinal degeneration follow a rapid progression compared with the human disease. We have observed significant levels of gene expression in retinal flatmounts from neonatal mice injected with AAV9-2YF 1 week post injection and steady levels of gene expression by the second week after the injection. This time course should enable gene replacement therapies before significant loss of photoreceptors and remodeling of the retina occurs in rodent models of blindness.
MATERIALS AND METHODS

Generation of recombinant AAV vectors
AAV vectors were produced by the plasmid co-transfection method. 26 Recombinant AAV was purified via iodixanol gradient ultracentrifugation as described previously 7 and titered by quantitative PCR relative to standards. Each vector contained a self-complimentary genome encoding GFP under the control of a ubiquitous CAG promoter or a single-stranded genome with GFP under the control of mouse rhodopsin promoter.
Intravascular injections
C57/BL/6 littermates were used for all studies. The postnatal day-1 pups were immobilized, and an operating microscope was used to visualize the tail vain. A total of 4Â10 11 Dnase-resistant particles of AAV9-scCAG-GFP, AAV9-1YF-scCAG-GFP, AAV9-2YF-scCAG-GFP or AAV9-2YF-Rho-GFP were injected in 10 ml volume. A correct injection was verified by noting blanching of the vein. After the injection, pups were allowed to recover for several minutes on a 371C heating pad before being returned to their cages.
RT-PCR
Animals were humanely euthanized, and one retina was collected from n¼5 (AAV9), n¼4 (AAV9-1YF) or n¼5 (AAV9-2YF) mice. RNA was extracted and subjected to DNase digestion, and the resulting RNA was used to create cDNA. RT-PCR for GFP, as well as the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase as an internal control, was performed on samples in triplicate using validated primers. The ddCT method was used to calculate fold difference of GFP expression normalized to AAV9. An uninjected wild-type mouse retina served as a negative control.
Fundus photography
Fundus imaging was performed 2-8 weeks after injection (Micron II; Phoenix Research Labs Inc., Pleasanton, CA, USA). Pupils were dilated for fundus imaging with phenylephrine (2.5%) and atropine sulfate (1%).
Flatmounts
Retinal flatmounts were prepared by detaching the retina from the RPE. Radial cuts were introduced to flatten the tissue. The retinas were positioned with either the RGC or the photoreceptor side up to allow confocal imaging from both directions.
Peanut agglutinin labeling
Fixed retinas were rinsed 3Â in phosphate-buffered saline before blocking and labeling with peanut agglutinin conjugated to Alexa-594 (1:40, Invitrogen, Carlsbad, CA, USA; Molecular Probes, Carlsbad, CA, USA) for 1 h. After rinsing, relief cuts were introduced and retinas were mounted for imaging.
Cryosections
Eyes were enucleated and immersion fixed in 10% formalin. The cornea and lens were removed, and the resulting eye-cups were cryoprotected in 30% sucrose before embedding in optimal cutting temperature medium for cutting.
Immunolabeling
Retinal cryosections were blocked in 1% bovine serum albumin, 0.5% Triton X-100 and 2% normal donkey serum for 2-3 h and treated with a rabbit anti-GFP monoclonal antibody at 1:500 (Invitrogen) and/or mouse anti-NeuN (MAB377, Chemicon, Billerica, MA, USA) in blocking solution overnight at 4 1C. After three phosphate-buffered saline washes, Alexa-488-conjugated antirabbit secondary antibody (Invitrogen) was applied at a 1:1000 dilution in blocking solution for 2 h at room temperature. The results were examined by confocal microscopy (LSM5; Carl Zeiss Microimaging, Peabody, MA, USA). 
